White DE - Search Results

1

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer.

Belldegrun A, Webb DE, Austin HA 3rd, Steinberg SM, White DE, Linehan WM, Rosenberg SA. Belldegrun A, et al. Among authors: white de. Ann Intern Med. 1987 Jun;106(6):817-22. doi: 10.7326/0003-4819-106-6-817. Ann Intern Med. 1987. PMID: 3495213

2

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

Weber JS, Yang JC, Topalian SL, Schwartzentruber DJ, White DE, Rosenberg SA. Weber JS, et al. Among authors: white de. J Clin Oncol. 1992 Jan;10(1):33-40. doi: 10.1200/JCO.1992.10.1.33. J Clin Oncol. 1992. PMID: 1727923

3

Thyroid dysfunction associated with immunotherapy for patients with cancer.

Schwartzentruber DJ, White DE, Zweig MH, Weintraub BD, Rosenberg SA. Schwartzentruber DJ, et al. Among authors: white de. Cancer. 1991 Dec 1;68(11):2384-90. doi: 10.1002/1097-0142(19911201)68:11<2384::aid-cncr2820681109>3.0.co;2-a. Cancer. 1991. PMID: 1933775

4

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

Fisher B, Keenan AM, Garra BS, Steinberg SM, White DE, DiBisceglie AM, Hoofnagle JH, Yolles P, Rosenberg SA, Lotze MT. Fisher B, et al. Among authors: white de. J Clin Oncol. 1989 Dec;7(12):1852-62. doi: 10.1200/JCO.1989.7.12.1852. J Clin Oncol. 1989. PMID: 2585024

5

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.

Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Rosenberg SA, et al. Among authors: white de. Ann Surg. 1989 Oct;210(4):474-84; discussion 484-5. doi: 10.1097/00000658-198910000-00008. Ann Surg. 1989. PMID: 2679456 Free PMC article.

6

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE. Rosenberg SA, et al. Among authors: white de. J Clin Oncol. 1989 Dec;7(12):1863-74. doi: 10.1200/JCO.1989.7.12.1863. J Clin Oncol. 1989. PMID: 2685181 Clinical Trial.

7

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Ettinghausen SE, et al. Among authors: white de. Blood. 1987 Jun;69(6):1654-60. Blood. 1987. PMID: 3495302 Free article.

8

The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.

MacFarlane MP, Yang JC, Guleria AS, White RL Jr, Seipp CA, Einhorn JH, White DE, Rosenberg SA. MacFarlane MP, et al. Among authors: white rl jr, white de. Cancer. 1995 Feb 15;75(4):1030-7. doi: 10.1002/1097-0142(19950215)75:4<1030::aid-cncr2820750420>3.0.co;2-5. Cancer. 1995. PMID: 7842405

9

Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma.

White RL Jr, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, Rosenberg SA. White RL Jr, et al. Among authors: white de. Cancer. 1994 Dec 15;74(12):3212-22. doi: 10.1002/1097-0142(19941215)74:12<3212::aid-cncr2820741221>3.0.co;2-i. Cancer. 1994. PMID: 7982185

10

Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.

Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, White RL, Steinberg SM, White DE, Einhorn JH, et al. Guleria AS, et al. Among authors: white rl, white de. J Clin Oncol. 1994 Dec;12(12):2714-22. doi: 10.1200/JCO.1994.12.12.2714. J Clin Oncol. 1994. PMID: 7989949 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results